Figure 4.

In vitro anti-tumor effect of TKI258 in LoVo and HT-29 cells. A. The GroCell-viability assay (MTT Assay) was performed using the multi-target FGFR inhibitor, TKI258. The KRAS mutant LoVo cells (IC₅₀ = 130 nM) were more sensitive to TKI258 than the BRAF mutant HT-29 cells (IC₅₀ = 2,530 nM). B, C. Anchorage-independent colony-formation assay performed using TKI258 to compare LoVo and HT-29 cell lines. Almost no colonies were formed by the KRAS mutant LoVo cells after adding 500 nM TKI258, and the result was statistically significant; by contrast, the BRAF mutant HT-29 cell line was not affected by the drug treatment. *p < 0.05.